Scribe Therapeutics Inc. Common Stock SCTX
$15.70
+1.42%
at last close
Market Cap$297.23 million
P/E Ratio—
Div Yield—
Volume324.5K
52-Week Range
$13.50$39.60
Analyst Ratings
- Consensus
- Buy — 4 Buy · 0 Hold · 0 Sell (4 analysts)
- Avg. Price Target
- $51.75 (+229.6% upside)
Key Stats
- Today's Range
- $15.29 – $16.44
- 50-Day Range
- $13.50 – $35.40
- 52-Week Range
- $13.50 – $39.60
- Volume
- 324K shs
- Average Volume
- 451K shs
- Market Cap
- $297.23 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 1.39%
- Days to Cover
- 1.34
About Scribe Therapeutics Inc. Common Stock
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.
Related Stocks
Compare head-to-head: SCTX vs AMGN·SCTX vs MRNA·SCTX vs HALO·SCTX vs KYMR
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.